ADB International Group Inc. Announces Partnership with Austen BioInnovation Institute to Bring E-QURE BST™ Wound Healing Device to U.S. Market

SAN ANTONIO, July 21, 2014 /PRNewswire-USNewswire/ ADB International Group Inc.: OTCQB: ADBI (ADBI or the Company) today announced a partnership with Austen BioInnovation Institute in Akron (ABIA or the Institute), for the purpose of bringing ADBI s E-QURE BST™, a bioelectrical signal therapy device (the E-QURE BST Device), to the U.S. market. The Institute, which has significant expertise in wound healing, clinical trial development and regulatory operations, will conduct a clinical trial that will include 70 patients in a double-arm, controlled, randomized, multi-center study to assess the safety and efficacy of the E-QURE BST Device in subjects with stage II & III Pressure and Venus Stasis ulcers, as an adjunct to the Standard of Care. The Company s E-QURE BST Device currently is marketed in Europe for similar indications. It aims to accelerate healing of hard-to-heal chronic wounds by delivering electrical stimulation to an injury site and thus effectively mimicking the el
http://bit.ly/1u8aT4j